EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY 4.0

Nabiximols in Multiple Sclerosis: Beyond Spasticity—An Exploratory Systematic Review and Meta-Analysis of Symptomatic Outcomes

Dénes Kleiner, István László Horváth iD, Dóra Mátis, Rita Nagy, Dorottya Gergő iD, Katalin Lugosi, Gábor Fazekas iD, Péter Fehérvári, Péter Hegyi, Dezső Csupor iD

Medical Sciences · 25.06.2026 · 14 (3) · 346

DOI: 10.3390/medsci14030346 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Medical Sciences, online erschienen am 25.06.2026. Verfasst von Dénes Kleiner und 9 weiteren Autor:innen. Beteiligte Einrichtung: University Pharmacy, Department of Pharmacy Administration, Semmelweis University, Hőgyes Endre utca 7-9., 1092 Budapest, Hungary. Hauptthemen laut MEDLINE: Multiple Sclerosis, Cannabidiol, Dronabinol, Muscle Spasticity. Die Arbeit nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Gedeon Richter Talentum Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background/Objectives: Nabiximols, a standardized extract of Cannabis sativa, has been approved as an add-on therapy for patients with moderate to severe spasticity associated with multiple sclerosis (MS). Moreover, current Italian treatment algorithms suggest that cannabis-based therapies may have further relevance in the management of MS. The aim of our systematic review and meta-analysis was to assess the effectiveness of nabiximols in relieving symptoms other than spasticity in adult MS patients.

Methods

A systematic search was conducted in Web of Science, MEDLINE (via PubMed), Cochrane CENTRAL and Embase on September 10, 2025. Study selection was performed according to the predefined PROSPERO protocol (CRD42022329952). Data were combined into a common denominator and examined using a random-effects model with meta-regression expressed as mean difference (MD) and a 95% confidence interval (CI). Risk of bias was assessed using the Cochrane risk of bias instrument (RoB2) and the Risk Of Bias In Non-randomized Studies of Interventions (ROBINS-I) tool.

Results

Of the 49 eligible articles, 25 were included in the statistical analysis (2949 patients). Significant improvements in spasm quality (MD = −16.87; 95% CI = (−29.75)–(−3.99)), bladder function (MD = −16.38; 95% CI = (−22.18)–(−10.58)), sleep disruption (MD = −15.75; 95% CI = (−22.02)–(−9.49)) and gait function (timed walk MD(s) = −5.31; 95% CI(s) = (−9.88)–(−0.74)) were observed. Time-dependency was not significant. The subject global impression of change (SGIC) improved significantly after the first month (odds ratio (OR) = 1.69; 95% CI = (1.30)–(2.18)).

Conclusion

Beyond spasticity, nabiximols may represent a signal of benefit for bladder function, sleep disruption, spasm quality, and gait function in MS, in line with the “spasticity-plus” concept. However, the evidence certainty was low to very low, and these findings should be considered exploratory.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Multiple SclerosisCannabidiolDronabinolMuscle SpasticityHumansDrug CombinationsTreatment Outcome

Stichwörter der Autor:innen

SativexTHC/CBDbladder functionmultiple sclerosissleep disruptionspasms

Substanzen

CannabidiolnabiximolsDronabinolDrug Combinations

Autor:innen und Institutionen

  • University Pharmacy, Department of Pharmacy Administration, Semmelweis University, Hőgyes Endre utca 7-9., 1092 Budapest, Hungary.
  • Centre for Translational Medicine, Semmelweis University, Baross utca 22, 1085 Budapest, Hungary.
  • Heim Pál National Pediatric Institute, 1089 Budapest, Hungary.
  • Department of Pharmacognosy, Semmelweis University, Üllői út 26., 1085 Budapest, Hungary.
  • Multiple Sclerosis Centre, Bajcsy-Zsilinszky Hospital, Maglódi út 89-91, 1106 Budapest, Hungary.
  • Rehabilitation Clinic, Semmelweis University, Szanatórium utca 19, 1121 Budapest, Hungary.

ORCID-Profile: István László Horváth, Dorottya Gergő, Gábor Fazekas, Dezső Csupor

Förderung

  • Gedeon Richter Talentum Foundation

Zitieren

APA

Kleiner, D., Horváth, I. L., Mátis, D., Nagy, R., Gergő, D., Lugosi, K., Fazekas, G., Fehérvári, P., Hegyi, P., & Csupor, D. (2026). Nabiximols in Multiple Sclerosis: Beyond Spasticity—An Exploratory Systematic Review and Meta-Analysis of Symptomatic Outcomes. Medical Sciences, 14(3), 346. https://doi.org/10.3390/medsci14030346

Vancouver

Kleiner D, Horváth IL, Mátis D, Nagy R, Gergő D, Lugosi K, et al. Nabiximols in Multiple Sclerosis: Beyond Spasticity—An Exploratory Systematic Review and Meta-Analysis of Symptomatic Outcomes. Medical Sciences. 2026;14(3):346. doi:10.3390/medsci14030346

BibTeX
@article{Kleiner2026,
  author = {Kleiner, Dénes and Horváth, István László and Mátis, Dóra and Nagy, Rita and Gergő, Dorottya and Lugosi, Katalin and Fazekas, Gábor and Fehérvári, Péter and Hegyi, Péter and Csupor, Dezső},
  title = {Nabiximols in Multiple Sclerosis: Beyond Spasticity—An Exploratory Systematic Review and Meta-Analysis of Symptomatic Outcomes},
  journal = {Medical Sciences},
  year = {2026},
  volume = {14},
  number = {3},
  pages = {346},
  doi = {10.3390/medsci14030346}
}
Kostenlos starten →